These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 12050592)
61. Drugs, industry, and academia. Fitzgerald GA Science; 2008 Jun; 320(5883):1563. PubMed ID: 18566251 [No Abstract] [Full Text] [Related]
62. [Product innovation in the pharmaceutical sector. III.(II). The pharmaceutical sector]. Cavara C Boll Chim Farm; 1991 Nov; 130(10):409-21. PubMed ID: 1805876 [No Abstract] [Full Text] [Related]
63. [Quality control of drugs and drug specialties]. Meyrat A Pharm Acta Helv; 1967 Jan; 42(1):14-36. PubMed ID: 6043416 [No Abstract] [Full Text] [Related]
64. The impact of microwave synthesis on drug discovery. Kappe CO; Dallinger D Nat Rev Drug Discov; 2006 Jan; 5(1):51-63. PubMed ID: 16374514 [TBL] [Abstract][Full Text] [Related]
65. Dry blending process scale-up for a very low dose drug candidate. Wu LS; Pang J; Chen JG; Hussain MA AAPS PharmSciTech; 2000 Aug; 1(3):E-TN2. PubMed ID: 14727902 [No Abstract] [Full Text] [Related]
66. Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity? Ivanenkov YA; Zagribelnyy BA; Aladinskiy VA J Med Chem; 2019 Nov; 62(22):10026-10043. PubMed ID: 31188596 [TBL] [Abstract][Full Text] [Related]
67. Current and future impact of green chemistry on the pharmaceutical industry. Fortunak JM Future Med Chem; 2009 Jul; 1(4):571-5. PubMed ID: 21426025 [No Abstract] [Full Text] [Related]
68. Drug discovery. Kennedy D Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461 [No Abstract] [Full Text] [Related]
69. [New methods in pharmaceutical research: combinatorial chemistry and high throughput screening]. Schirlin D; Galvan M; Le Fur G Bull Acad Natl Med; 2007; 191(4-5):727-36; discussion 736-7. PubMed ID: 18225426 [TBL] [Abstract][Full Text] [Related]
72. A timely re-examination of drug polymorphism in pharmaceutical development and regulation. Grant DJ; Byrn SR Adv Drug Deliv Rev; 2004 Feb; 56(3):237-9. PubMed ID: 14962580 [No Abstract] [Full Text] [Related]
73. [Importance of interfacial characteristics in pharmaceutical technology]. Dredán J; Csóka G; Marton S; Antal I Acta Pharm Hung; 2003; 73(3):147-51. PubMed ID: 15112437 [TBL] [Abstract][Full Text] [Related]
74. Monoclonal antibody successes in the clinic. Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394 [TBL] [Abstract][Full Text] [Related]
75. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report. Karanth H; Shenoy VS; Murthy RR AAPS PharmSciTech; 2006 Oct; 7(4):87. PubMed ID: 17233539 [TBL] [Abstract][Full Text] [Related]
76. [New active agents. The composition of commercial pharmaceutical specialties in 2001]. Bernard M J Pharm Belg; 2002; 57(1):1-13. PubMed ID: 11913094 [No Abstract] [Full Text] [Related]
77. Advances in Medicinal Chemistry from Analytical Perspectives. Ozkan SA Curr Med Chem; 2018; 25(33):3954-3955. PubMed ID: 30378490 [No Abstract] [Full Text] [Related]
78. Surviving the blockbuster syndrome. Service RF Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490 [No Abstract] [Full Text] [Related]
79. Optimizing drug formulation - SMi's third annual conference. Hookes L IDrugs; 2008 Apr; 11(4):260-2. PubMed ID: 18379958 [No Abstract] [Full Text] [Related]